Clinical Trials Logo
  1. Home
  2. Mitochondrial Myopathy
  3. NCT02895789

Oxidative Capacity and Exercise Tolerance in Ambulatory SMA

Spinal Muscular Atrophy Type 3 Clinical Trial

Official title:
Evaluation of Oxidative Capacity and Exercise Tolerance in Ambulatory Patients With Spinal Muscular Atrophy (SMA)

Clinical Trial Summary

This proposal will focus on (1) estimating oxidative capacity of specific muscle groups during exercise using near infrared spectroscopy and (2) describing body composition to better understand exercise capacity and mitochondrial function in ambulatory spinal muscular atrophy (SMA) patients and disease controls. It is a 6-month observational study including 14 ambulatory SMA patients, 14 ambulatory patients with mitochondrial myopathy, and 14 healthy controls.

Clinical Trial Description

Spinal Muscular Atrophy (SMA) is a progressive, recessively-inherited neuromuscular disease characterized by weakness and muscle atrophy due to the loss of spinal cord motor neurons. The results from this study would provide preliminary data, using non-invasive methods, on oxidative capacity in ambulatory SMA patients and disease controls to aid in the design of exercise intervention studies. Furthermore, this information would link previous laboratory and preclinical findings of mitochondrial depletion in SMA to the clinical condition and provide important information for future studies designed to improve oxidative capacity and fitness in SMA patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02895789
Study type Observational
Source Columbia University
Contact
Status Completed
Phase
Start date November 2016
Completion date January 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT04193085 - Wearable Technology to Assess Gait Function in SMA and DMD
Not yet recruiting NCT06300996 - Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb N/A
Terminated NCT03819660 - Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3 Phase 2
Recruiting NCT05272969 - Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
Recruiting NCT05544994 - The Effect of Aerobic Exercise Training in Patients With Type III Spinal Muscular Atrophy N/A
Completed NCT02227823 - Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3 Phase 2
Active, not recruiting NCT05156320 - Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam Phase 3
Recruiting NCT03709784 - Spinraza in Adult Spinal Muscular Atrophy
Terminated NCT03056144 - Whole Body Vibration Therapy in Children With Spinal Muscular Atrophy N/A
Recruiting NCT05430113 - Spinal Cord Stimulation in Spinal Muscular Atrophy N/A
Completed NCT03921528 - An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy Phase 2
Active, not recruiting NCT05626855 - Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab-ONYX Phase 3
Completed NCT04907162 - Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders